354 related articles for article (PubMed ID: 10371230)
1. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
[TBL] [Abstract][Full Text] [Related]
2. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
4. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
Shorr AF; Ramage AS
Crit Care Med; 2001 Sep; 29(9):1659-65. PubMed ID: 11546959
[TBL] [Abstract][Full Text] [Related]
5. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
9. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.
McLeod RS; Geerts WH; Sniderman KW; Greenwood C; Gregoire RC; Taylor BM; Silverman RE; Atkinson KG; Burnstein M; Marshall JC; Burul CJ; Anderson DR; Ross T; Wilson SR; Barton P;
Ann Surg; 2001 Mar; 233(3):438-44. PubMed ID: 11224634
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
Hawkins DW; Langley PC; Krueger KP
Am J Health Syst Pharm; 1997 May; 54(10):1185-90. PubMed ID: 9161627
[TBL] [Abstract][Full Text] [Related]
14. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
17. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
Offord R; Lloyd AC; Anderson P; Bearne A
Pharm World Sci; 2004 Aug; 26(4):214-20. PubMed ID: 15446778
[TBL] [Abstract][Full Text] [Related]
19. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Wellington K; McClellan K; Jarvis B
Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
[TBL] [Abstract][Full Text] [Related]
20. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
